Analysts forecast that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will announce sales of $461.36 million for the current fiscal quarter, Zacks reports. Eight analysts have issued estimates for Jazz Pharmaceuticals’ earnings, with the highest sales estimate coming in at $490.40 million and the lowest estimate coming in at $449.47 million. Jazz Pharmaceuticals posted sales of $436.40 million during the same quarter last year, which would indicate a positive year over year growth rate of 5.7%. The business is expected to announce its next quarterly earnings results on Tuesday, February 26th.
On average, analysts expect that Jazz Pharmaceuticals will report full-year sales of $1.88 billion for the current financial year, with estimates ranging from $1.86 billion to $1.92 billion. For the next year, analysts anticipate that the firm will report sales of $2.07 billion, with estimates ranging from $1.99 billion to $2.19 billion. Zacks’ sales averages are a mean average based on a survey of analysts that cover Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share for the quarter, topping analysts’ consensus estimates of $3.32 by $0.26. The company had revenue of $469.37 million for the quarter, compared to analysts’ expectations of $482.64 million. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The business’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same period last year, the firm posted $3.22 earnings per share.
JAZZ has been the topic of several research reports. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $213.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 8th. Cantor Fitzgerald set a $203.00 price objective on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 7th. Stifel Nicolaus boosted their price objective on shares of Jazz Pharmaceuticals from $180.00 to $205.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. BMO Capital Markets boosted their price objective on shares of Jazz Pharmaceuticals from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Wednesday, August 8th. Finally, Seaport Global Securities reaffirmed a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 9th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $189.76.
In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,300 shares of Jazz Pharmaceuticals stock in a transaction on Friday, September 21st. The shares were sold at an average price of $164.36, for a total value of $213,668.00. Following the sale, the chief executive officer now directly owns 281,215 shares in the company, valued at approximately $46,220,497.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Patrick G. Enright sold 10,130 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $168.76, for a total transaction of $1,709,538.80. Following the completion of the sale, the director now owns 19,884 shares in the company, valued at $3,355,623.84. The disclosure for this sale can be found here. Insiders sold a total of 16,730 shares of company stock worth $2,773,011 over the last quarter. Company insiders own 3.90% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Stratos Wealth Partners LTD. acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $106,000. Riverhead Capital Management LLC acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $113,000. Financial Enhancement Group LLC acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $140,000. Tiverton Asset Management LLC acquired a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at $198,000. Finally, Paloma Partners Management Co acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $224,000. Hedge funds and other institutional investors own 92.30% of the company’s stock.
JAZZ opened at $151.20 on Monday. The firm has a market capitalization of $9.12 billion, a P/E ratio of 15.82, a P/E/G ratio of 0.91 and a beta of 1.06. Jazz Pharmaceuticals has a 12 month low of $130.15 and a 12 month high of $184.00. The company has a current ratio of 4.29, a quick ratio of 4.16 and a debt-to-equity ratio of 0.52.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Read More: What is Cost of Capital?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.